Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia

Blood

Volumn 116, Issue 20, 2010, Pages 4251-4261

  Kornblau, Steven M ^a   McCue, David ^a   Singh, Neera ^a   Chen, Wenjing ^a   Estrov, Zeev ^a   Coombes, Kevin R ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CLOFARABINE; CXCL11 CHEMOKINE; CYTARABINE; FIBROBLAST GROWTH FACTOR 2; FLUDARABINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR ALPHA; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; INTERLEUKIN 9; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR BB; RANTES; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD CELL COUNT; CANCER SURVIVAL; CELL ACTIVATION; CONTROLLED STUDY; CYTOGENETICS; CYTOKINE RELEASE; DRUG MEGADOSE; FEMALE; GENDER; HUMAN; HUMAN CELL; INFECTION; LEUKEMIA CELL; LEUKEMIA REMISSION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

EID: 78549250108     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-01-262071     Document Type: Article

References (48)

1. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860-867.
2. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539-545. (Pubitemid 32173595)
3. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer. 2004;4(1):11-22.
4. Baker SJ, Rane SG, Reddy EP. Hematopoietic cytokine receptor signaling. Oncogene. 2007;26(47):6724-6737.
5. Van Etten RA. Aberrant cytokine signaling in leukemia. Oncogene. 2007;26(47):6738-6749.
6. Kornblau SM, Womble M, Jackson CE, Chen W, Estey EH, Andreeff M. Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood. 2006;108(7):2358-2365. (Pubitemid 44497520)
7. Hayakawa F, Towatari M, Kiyoi H, et al. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene. 2000;19(5):624-631. (Pubitemid 30102913)
8. Kornblau SM, Tibes R, Qiu Y, et al. Functional proteomic profiling of AML predicts response and survival. Blood. 2009;113(1):154-164.
9. Tomasson MH, Xiang Z, Walgren R, et al. Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. Blood. 2008;111(9):4797-4808.
10. Loriaux MM, Levine RL, Tyner JW, et al. High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood. 2008;111(9):4788-4796.
11. Lotem J, Sachs L. Control of apoptosis in hematopoiesis and leukemia by cytokines, tumor suppressor and oncogenes. Leukemia. 1996;10(6):925-931. (Pubitemid 26235921)
12. Russell N. Autocrine growth factors and leukemic haemopoiesis. Blood Rev. 1992;6(3):149-156.
13. Hsu H, Lee Y, Tsai W, et al. Circulating levels of thrombopoietic and inflammatory cytokines in patients with acute myeloblastic leukemia and myelodysplastic syndrome. Oncology. 2002;63(1):64-69.
14. Elbaz O, Shaltoult A. Implication of granulocytemacrophage colony stimulating factor (GM-CSF) and interleukin-3 (IL-3) in children with acute myeloid leukaemia (AML): malignancy. Hematology. 2001;1(5):383-388.
15. Tao M, Li B, Nayini J, et al. SCF, IL-1beta, IL-1ra and GM-CSF in the bone marrow and serum of normal individuals and of AML and CML patients. Cytokine. 2000;12(6):699-707. (Pubitemid 30453501)
16. Tsimberidou AM, Estey E, Wen S, et al. The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes. Cancer. 2008;113(7):1605-1613.
17. Estrov Z, Roifman C, Mills G, Grunberger T, Gelfand EW, Freedman MH. The regulatory role of interleukin 2-responsive T lymphocytes on human marrow granulopoiesis. Blood. 1987;69(4):1161-1166.
18. Ferrajoli A, Talpaz M, Zipf TF, et al. Inhibition of acute myelogenous leukemia progenitor proliferation by macrophage inflammatory protein 1-alpha. Leukemia. 1994;8(5):798-805.
19. Estrov Z, Kurzrock R, Estey E, et al. Inhibition of acute myelogenous leukemia blast proliferation by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors. Blood. 1992;79(8):1938-1945.
20. Estrov Z, Black RA, Sleath PR, et al. Effect of interleukin-1 beta converting enzyme inhibitor on acute myelogenous leukemia progenitor proliferation. Blood. 1995;86(12):4594-4602.
21. Krutzik PO, Irish JM, Nolan GP, Perez OD. Analysis of protein phosphorylation and cellular signaling events by flow cytometry: techniques and clinical applications. Clin Immunol. 2004;110(3):206-221.
22. Bruserud O, Ryningen A, Olsnes AM, et al. Sub-classification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells. Haematologica. 2007;92(3):332-341. (Pubitemid 350143542)
23. Panteli K, Hatzimichael E, Bouranta P, et al. Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases. Br J Haematol. 2005;130(5):709-715. (Pubitemid 43906643)
24. Gwang K, Kyun SS, Hwan K, et al. Clinical implications of angiogenic factors in patients with acute or chronic leukemia: hepatocyte growth factor levels have prognostic impact, especially in patients with acute myeloid leukemia. Leuk Lymphoma. 2005;46(16):885-891.
25. Aguayo A, Kantarjian H, Estey E, et al. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. Cancer. 2002;95(9):1923-1930.
26. de Jager W, Velthuis H, Prakken BJ, Kuis W, Rijkers GT. Simultaneous detection of 15 human cytokines in a single sample of stimulated peripheral blood mononuclear cells. Clin Diagn Lab Immunol. 2003;10(1):133-139.
27. Linkov F, Lisovich A, Yurkovetsky Z, et al. Early detection of head and neck cancer: development of a novel screening tool using multiplexed immunobead-based biomarker profiling. Cancer Epidemiol Biomarkers Prev. 2007;16(1):102-107. (Pubitemid 46174271)
28. Lambeck AJ, Crijns AP, Leffers N, et al. Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: a potential role for interleukin 7. Clin Cancer Res. 2007;13(8):2385-2391. (Pubitemid 46698588)
29. Zeh HJ, Winikoff S, Landsittel DP, et al. Multianalyte profiling of serum cytokines for detection of pancreatic cancer. Cancer Biomark. 2005;1(6):259-269.
30. Gottschalk PG, Dunn JR. Measuring parallelism, linearity, and relative potency in bioassay and immunoassay data [abstract]. J Biopharm Stat. 2005;15(3):437-463.
31. Mardia KV, Kent JT, Bibby JM. Multivariate Analysis. San Diego, CA: Academic Press; 1979:213-254.
32. Wang J, Wen S, Symmans WF, Pusztai L, Coombes KR. The bimodality index: a criterion for discovering and ranking bimodal signatures from cancer gene expression profiling data. Cancer Inform. 2009;7:199-216.
33. Stroncek D, Slezak S, Khuu H, et al. Proteomic signature of myeloproliferation and neutrophilia: analysis of serum and plasma from healthy subjects given granulocyte colony-stimulating factor. Exp Hematol. 2005;33(10):1109-1117. (Pubitemid 41416959)
34. Park HH, Kim M, Lee BH, et al. Intracellular IL-4, IL-10, and IFN-gamma levels of leukemic cells and bone marrow T cells in acute leukemia. Ann Clin Lab Sci. 2006;36(1):7-15.
35. Bruserud O, Mentzoni L, Buhring H-J, Pawelec G. Effects of hematopoietic growth factors on interleukin 6 secretion by blast cells derived from acute myelogenous leukemia patients. Acta Haematol. 1996;96(3):155-161. (Pubitemid 26319298)
36. Bruserud O. IL-4, IL-10 and IL-13 in acute myelogenous leukemia. Cytokines Cell Mol Ther. 1998;4(3):187-198.
37. Pruneri G, Bertolini F, Soligo D, et al. Angiogenesis in myelodysplastic syndromes. Br J Cancer. 1999;81(8):1398-1401.
38. Kitagawa M, Saito I, Kuwata T, et al. Overexpression of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma by bone marrow cells from patients with myelodysplastic syndromes. Leukemia. 1997;11(12):2049-2054. (Pubitemid 28043688)
39. Vinante F, Rigo A, Tecchio C, et al. Serum levels of p55 and p75 soluble TNF receptors in adult acute leukaemia at diagnosis: correlation with clinical and biological features and outcome. Br J Haematol. 1998;102(4):1025-1034.
40. Shetty V, Mundle S, Alvi S, et al. Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes. Leuk Res. 1996;20(11):891-900.
41. Stifter G, Heiss S, Gastl G, Tzankov A, Stauder R. Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis. Eur J Haematol. 2005;75(6):485-491. (Pubitemid 41687782)
42. Aggarwal BB, Takada Y. Pro-apoptotic and antiapoptotic effects of tumor necrosis factor in tumor cells. In: Platanias LC, ed. Cytokines and Cancer. New York: Springer; 2005:103-127.
43. Beg AA, Baltimore D. An essential role for NF-kappaB in preventing TNF-alpha induced cell death. Science. 1996;274(5288):782-784. (Pubitemid 26398258)
44. Elbaz O, Budel LM, Hoogerbrugge H, et al. Tumor necrosis factor downregulates granulocyte-colony-stimulating factor receptor expression on human acute myeloid leukemia cells and granulocytes. J Clin Invest. 1991;87:(3)838-841.
45. Appelbaum FR. Immunobiologic therapies for myelodysplastic syndrome. Best Pract Res Clin Haematol. 2004;17(4):653-661.
46. Hamilton JA. GM-CSF in inflammation and autoimmunity. Trends Immunol. 2002;23(8):403-408.
47. Lowenberg B, Touw IP. Hematopoietic growth factors and their receptors in acute leukemia. Blood. 1993;81(2):281-292.
48. Panoskaltsis N, Reid CD, Knight SC. Quantification and cytokine production of circulating lymphoid and myeloid cells in acute myelogenous leukaemia. Leukemia. 2003;17(4):716-730. (Pubitemid 36519368)